Evidence map›Paper›PMID 40518662›Full record

ArticleThe oncologist2025

Patient-reported tolerance of 90 days of preoperative endocrine therapy: results from the preoperative window of endocrine therapy to inform radiation therapy decisions trial.

Trish Millard, Lena M Turkheimer, Jenna Schlefman, Gina R Petroni, David Brighton, Shayna L Showalter

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Trish MillardDepartment of Medicine, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0002-6504-5387
Lena M TurkheimerDepartment of Surgery, University of Virginia, Charlottesville, VA, USA.
Jenna SchlefmanDepartment of Medicine, University of Virginia, Charlottesville, VA, USA.
Gina R PetroniDepartment of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.
David BrightonDepartment of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.
Shayna L ShowalterDepartment of Surgery, University of Virginia, Charlottesville, VA, USA.

Funding

Patient-Centered Insights from the POWER Trial: Pre-Operative Window of Adjuvant Endocrine Therapy to Inform Radiation Therapy Decisions in Older Women with Early-Stage Breast CancerR21CA277311 · NCI · UNIVERSITY OF VIRGINIA · PI SHOWALTER, SHAYNA LEFRAK · 2023 to 2024
$409k
American Cancer Society Institutional Research #IRG 81-001-26NCI NIH HHS R21 CA277311NIH HHS R21CA277311
6 · The paper itself

Abstract

backgroundProspective randomized data supports radiation omission in women ≥65 years who take adjuvant endocrine therapy (AET) following breast-conserving surgery. Many patients who omit radiation stop AET early due to side effects. In the POWER trial, a prospective single-arm study, patients took 90 days of preoperative endocrine therapy (pre-ET) to assess tolerance before making adjuvant treatment decisions. We hypothesized that patient-reported outcomes (PROs) during pre-ET would be heterogeneous and that 90 days was sufficient time for symptoms to develop. PATIENTS AND

methodsPRO data from POWER trial participants was obtained before, during, and after pre-ET, including health-related quality of life (HRQoL), depression, and ET symptoms using the EORTC-QLQ, CESD-R, and BCPT-SCL tools. PRO assessments were further analyzed after stratifying patients by high or low perceived sensitivity to medicine (PSM).

resultsPre-ET PROs were assessed for 75 participants. The majority (73.3%) reported symptoms during pre-ET. Only 10.7% had symptoms severe enough to stop pre-ET before 90 days. Vasomotor (42.7%) and musculoskeletal (41.3%) symptoms were the most common. HRQoL was preserved for 66.6% of participants. Patients with high PSM had more ET side effects.

conclusionsPatients developed similar side effects during pre-ET as those typically seen with AET. PROs and the impact of pre-ET on HRQoL were patient-dependent. A 90-day course of pre-ET is sufficient for patients to develop symptoms reflective of long-term AET. Future analyses will assess the association of pre-ET PROs with AET initiation and adherence.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsAgedAged, 80 and overFemaleHumansMiddle AgedPatient Reported Outcome MeasuresPreoperative CareProspective StudiesQuality of LifeAntineoplastic Agents, Hormonalbreast cancerendocrine therapypatient-reported outcomesradiation omission

Identifiers

PMID40518662
PMCPMC12269375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.